Flow Cytometric Analysis of T Lymphocyte Activation in CML Patients Under Imatinib Therapy

Ozcan, Muhit; Arslan, Önder; Gürman, Günhan; Goren Sahin, Deniz; KORKMAZ, Ayla; meriç, sema; Arat, Mutlu

doi:10.20515/otd. 532364

Flow Cytometric Analysis of T Lymphocyte Activation in CML Patients Under Imatinib Therapy

Deniz Gören ŞAHİN, (Bilim Üniversitesi, Tıp Fakültesi, Hematoloji Anabilim Dalı, İstanbul, Türkiye)

Ayla KORKMAZ, (Ankara Üniversitesi, Tıp Fakültesi, Hematoloji Anabilim Dalı, Ankara, Türkiye)

Sema Meriç, (Ankara Üniversitesi, Tıp Fakültesi, Hematoloji Anabilim Dalı, Ankara, Türkiye)

Günhan Gürman, (Ankara Üniversitesi, Tıp Fakültesi, Hematoloji Anabilim Dalı, Ankara, Türkiye)

Muhit Özcan, (Ankara Üniversitesi, Tıp Fakültesi, Hematoloji Anabilim Dalı, Ankara, Türkiye)

Önder Arslan, (Ankara Üniversitesi, Tıp Fakültesi, Hematoloji Anabilim Dalı, Ankara, Türkiye)

Mutlu Arat (İstanbul Şişli Florence Nightingale Hastaneleri, Hematopoetik Kök Hücre Merkezi İstanbul, Türkiye)

Osmangazi Tıp Dergisi

1 0

Yıl: 2020 Cilt: 42 Sayı: 2 Sayfa Aralığı: 180 - 187 Metin Dili: İngilizce DOI: 10.20515/otd. 532364 İndeks Tarihi: 01-04-2021

Flow Cytometric Analysis of T Lymphocyte Activation in CML Patients Under Imatinib Therapy

Öz:

To analyze T cell functions by flow cytometry and to evaluate the possible functional changes that might occur underimatinib therapy in CML patients. A total of 29 patients and 9 healthy control subjects were enrolled. Newly diagnosed patientshaving no treatment (group 1), patients receiving imatinib for 1 year (group 2) and patients receiving imatinib more than 1 year(group 3), healthy control subjects (group 4). IL-4 and IFN gamma expression on CD4+ cells; how much percentage of CD3+ Tcells were activated (CD3+CD69+); CD8+ T cells and the ratio and grade of expression of HLA-ABC and HLA-DR on those cellswere evaluated, respectively. There was no significant difference in terms of mean number of CD4+ cells between the groups.However, there was a tendency towards higher CD4+ cells in control group. IL-4 and IFN gamma were found not to be statisticallysignificant between the groups. Control group has lower IL-4 and IFN gamma expression values. Mean number of CD4+ cells,which did not express IL-4 and IFN gamma, were statistically higher in control group when compared to other groups. In controlgroup, % activation was decreased when compared to that of other groups. CD8+ cell ratio was found to be statistically lower in allpatient groups (p=0.001). The expression of HLA-ABC and HLA-DR on CD8+ cells were similar between the groups. We couldnot show any inhibitory effect of imatinib on T cell functions in concordance with clinical experience and safety profile.

Anahtar Kelime:

I matinib Tedavisi Alan Hastalarda T Lenfosit Aktivasyonunun Akım Sitometrik Analizi

Öz:

İmatinibin in vivo ortamda T lenfosit fonksiyonları üzerine olan etkileri akım sitometrik olarak değerlendirilmiştir. Çalışmaya toplam 29 KML hastası ve 9 sağlıklı birey dahil edilmiştir. KML hastaları kendi aralarında sırasıyla, yeni tanı almış ve tedavi görmeyen, 1 yıldır imatinib alan ve 1 yıldan uzun süredir imatinib alan hastalar olarak 3 gruba ayrılmıştır. CD4+ hücreler ve bu hücrelerdeki IL-4 ve IFNg ifadeleri, CD3+ T lenfositlerin % kaçının aktive edilmiş olduğu (CD3+CD69+), CD8+ hücreler ve bu hücrelerde HLA-ABC ve HLA-DR ifade eden hücrelerin oranı ve HLA-ABC ve HLA-DR ifadelerinin şiddeti değerlendirilmiştir. Gruplar arasında ortalama CD4 + hücre sayısı açısından anlamlı fark yoktu. Bununla birlikte, kontrol grubunda daha yüksek CD4 + hücrelerine doğru bir eğilim vardı. IL-4 ve IFN gama, gruplar arasında istatistiksel olarak anlamlı bulunmadı. Kontrol grubu daha düşük IL-4 ve IFN gama ifade değerlerine sahipti. IL-4 ve IFN gama ifade etmeyen ortalama CD4 + hücre sayısı kontrol grubunda diğer gruplara göre istatistiksel olarak daha yüksekti. Kontrol grubunda ise % aktivasyon diğer gruplara göre azdı. Tüm hasta gruplarında CD8 + hücre oranı istatistiksel olarak daha düşük bulundu (p = 0,001). HLA-ABC ve HLA-DR'nin CD8 + hücrelerinde ekspresyonu gruplar arasında benzerdi. İmatinibin sitokin sentezi üzerine herhangi bir etkisi gözlenmemiştir. İmatinib tedavisi altındaki hastalarda T lenfosit fonksiyonlarının etkilendiğine dair klinik belirgin gözlemler olmamakla birlikte, subklinik etki varlığı araştırma konusudur. Yapılan in vitro çalışmaların in-vivo korele olup olmadığının aydınlatılabilmesi için daha ileri çalışmalara gereksinim vardır.

Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

1. Shtivelman E, Lifshitz B, Gale RP, Canaani E. Fused transcript of abl and bcr genes in chronic myelogenous leukaemia. Nature. 1985;315:550-4.
2. Kurzrock R, Gutterman JU, Talpaz M. The molecular genetics of Philadelphia chromosome-positive leukemias. N Engl J Med. 1988;319:990-8.
3. Lugo TG, Pendergast AM, Muller AJ, Witte ON. Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science. 1990;247:1079-82.
4. Druker BJ, Tamura S, Buchdunger E, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med. 1996;2:561-6.
5. Kantarjian HM, O'Brien S, Cortes J, et al. Imatinib mesylate therapy improves survival in patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in the chronic phase: comparison with historic data. Cancer. 2003;98:2636-42.
6. Druker BJ, Guilhot F, O'Brien SG, Gathmann I, Kantarjian H, Gattermann N, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006;355:2408-17.
7. Barrett AJ. Mechanisms of the graft-versusleukemia reaction. Stem Cells. 1997;15:248- 58.
8. Cwynarski K, Laylor R, Macchiarulo E, Goldman J, Lombardi G, Melo JV, et al. Imatinib inhibits the activation and proliferation of normal T lymphocytes in vitro. Leukemia. 2004;18:1332-9.
9. Seggewiss R, Lore K, Greiner E, Magnusson MK, Price DA, Douek DC, et al. Imatinib inhibits T-cell receptor-mediated T-cell proliferation and activation in a dosedependent manner. Blood. 2005;105:2473-9.
10. Aswald JM, Lipton JH, Aswald S, Messner HA. Increased IFN-gamma synthesis by T cells from patients on imatinib therapy for chronic myeloid leukemia. Cytokines, cellular & molecular therapy. 2002;7:143-9.
11. Pendergast AM, Muller AJ, Havlik MH, Maru Y, Witte ON. BCR sequences essential for transformation by the BCR-ABL oncogene bind to the ABL SH2 regulatory domain in a non-phosphotyrosine-dependent manner. Cell. 1991;66:161-71.
12. Lim SH, Coleman S. Chronic myeloid leukemia as an immunological target. Am J Hematol. 1997;54:61-7.
13. Clark RE, Christmas SE. BCR-ABL fusion peptides and cytotoxic T cells in chronic myeloid leukaemia. Leuk Lymphoma. 2001;42:871-80.
14. Garicochea B, Chase A, Lazaridou A, Goldman JM. T lymphocytes in chronic myelogenous leukaemia (CML): no evidence of the BCR/ABL fusion gene detected by fluorescence in situ hybridization in 14 patients. Leukemia. 1994;8:1197-201.
15. Gao H, Lee BN, Talpaz M, Donato NJ, Cortes JE, Kantarjian HM, et al. Imatinib mesylate suppresses cytokine synthesis by activated CD4 T cells of patients with chronic myelogenous leukemia. Leukemia. 2005;19:1905-11.
16. Tsuda H, Yamasaki H. Type I and type II T cell profiles in chronic myelogenous leukemia. Acta haematologica. 2000;103:96-101.
17. Leder C, Ortler S, Seggewiss R, Einsele H, Wiendl H. Modulation of T-effector function by imatinib at the level of cytokine secretion. Exp Hematol. 2007;35:1266-71.
18. Dietz AB, Souan L, Knutson GJ, et al. Imatinib mesylate inhibits T-cell proliferation in vitro and delayed-type hypersensitivity in vivo. Blood. 2004;104:1094-9.
19. Appel S, Balabanov S, Brummendorf TH, Brossart P. Effects of imatinib on normal hematopoiesis and immune activation. Stem cells (Dayton, Ohio). 2005;23:1082-8.
20. Chen J, Schmitt A, Chen B, Rojewski M, Ringhoffer M, von Harsdorf S, et al. Imatinib impairs CD8+ T lymphocytes specifically directed against the leukemia-associated antigen RHAMM/CD168 in vitro. Cancer Immunol Immunother. 2007;56:849-61.
21. Brauer KM, Werth D, von Schwarzenberg K, Bringmann A, Kanz L, Grunebach F, et al. BCR-ABL activity is critical for the immunogenicity of chronic myelogenous leukemia cells. Cancer research. 2007;67:5489-97.
22. Mumprecht S, Matter M, Pavelic V, Ochsenbein AF. Imatinib mesylate selectively impairs expansion of memory cytotoxic T cells without affecting the control of primary viral infections. Blood. 2006;108:3406-13.

APA	Goren Sahin D, KORKMAZ A, meriç s, Gürman G, Ozcan M, Arslan Ö, Arat M (2020). Flow Cytometric Analysis of T Lymphocyte Activation in CML Patients Under Imatinib Therapy. , 180 - 187. 10.20515/otd. 532364
Chicago	Goren Sahin Deniz,KORKMAZ Ayla,meriç sema,Gürman Günhan,Ozcan Muhit,Arslan Önder,Arat Mutlu Flow Cytometric Analysis of T Lymphocyte Activation in CML Patients Under Imatinib Therapy. (2020): 180 - 187. 10.20515/otd. 532364
MLA	Goren Sahin Deniz,KORKMAZ Ayla,meriç sema,Gürman Günhan,Ozcan Muhit,Arslan Önder,Arat Mutlu Flow Cytometric Analysis of T Lymphocyte Activation in CML Patients Under Imatinib Therapy. , 2020, ss.180 - 187. 10.20515/otd. 532364
AMA	Goren Sahin D,KORKMAZ A,meriç s,Gürman G,Ozcan M,Arslan Ö,Arat M Flow Cytometric Analysis of T Lymphocyte Activation in CML Patients Under Imatinib Therapy. . 2020; 180 - 187. 10.20515/otd. 532364
Vancouver	Goren Sahin D,KORKMAZ A,meriç s,Gürman G,Ozcan M,Arslan Ö,Arat M Flow Cytometric Analysis of T Lymphocyte Activation in CML Patients Under Imatinib Therapy. . 2020; 180 - 187. 10.20515/otd. 532364
IEEE	Goren Sahin D,KORKMAZ A,meriç s,Gürman G,Ozcan M,Arslan Ö,Arat M "Flow Cytometric Analysis of T Lymphocyte Activation in CML Patients Under Imatinib Therapy." , ss.180 - 187, 2020. 10.20515/otd. 532364
ISNAD	Goren Sahin, Deniz vd. "Flow Cytometric Analysis of T Lymphocyte Activation in CML Patients Under Imatinib Therapy". (2020), 180-187. https://doi.org/10.20515/otd. 532364

APA	Goren Sahin D, KORKMAZ A, meriç s, Gürman G, Ozcan M, Arslan Ö, Arat M (2020). Flow Cytometric Analysis of T Lymphocyte Activation in CML Patients Under Imatinib Therapy. Osmangazi Tıp Dergisi, 42(2), 180 - 187. 10.20515/otd. 532364
Chicago	Goren Sahin Deniz,KORKMAZ Ayla,meriç sema,Gürman Günhan,Ozcan Muhit,Arslan Önder,Arat Mutlu Flow Cytometric Analysis of T Lymphocyte Activation in CML Patients Under Imatinib Therapy. Osmangazi Tıp Dergisi 42, no.2 (2020): 180 - 187. 10.20515/otd. 532364
MLA	Goren Sahin Deniz,KORKMAZ Ayla,meriç sema,Gürman Günhan,Ozcan Muhit,Arslan Önder,Arat Mutlu Flow Cytometric Analysis of T Lymphocyte Activation in CML Patients Under Imatinib Therapy. Osmangazi Tıp Dergisi, vol.42, no.2, 2020, ss.180 - 187. 10.20515/otd. 532364
AMA	Goren Sahin D,KORKMAZ A,meriç s,Gürman G,Ozcan M,Arslan Ö,Arat M Flow Cytometric Analysis of T Lymphocyte Activation in CML Patients Under Imatinib Therapy. Osmangazi Tıp Dergisi. 2020; 42(2): 180 - 187. 10.20515/otd. 532364
Vancouver	Goren Sahin D,KORKMAZ A,meriç s,Gürman G,Ozcan M,Arslan Ö,Arat M Flow Cytometric Analysis of T Lymphocyte Activation in CML Patients Under Imatinib Therapy. Osmangazi Tıp Dergisi. 2020; 42(2): 180 - 187. 10.20515/otd. 532364
IEEE	Goren Sahin D,KORKMAZ A,meriç s,Gürman G,Ozcan M,Arslan Ö,Arat M "Flow Cytometric Analysis of T Lymphocyte Activation in CML Patients Under Imatinib Therapy." Osmangazi Tıp Dergisi, 42, ss.180 - 187, 2020. 10.20515/otd. 532364
ISNAD	Goren Sahin, Deniz vd. "Flow Cytometric Analysis of T Lymphocyte Activation in CML Patients Under Imatinib Therapy". Osmangazi Tıp Dergisi 42/2 (2020), 180-187. https://doi.org/10.20515/otd. 532364